Description

Sunshine Biopharma, Inc. operates as a pharmaceutical and nutritional supplement company primarily dedicated to the research and development of innovative anticancer drugs. The company's pipeline includes Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin. This compound is currently in development to address a broad spectrum of cancers, such as leukemia, lymphoma, and tumors affecting the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver. Significantly, Adva-27a has also shown effectiveness against multidrug-resistant cancer cells, including those associated with pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma. Another key therapeutic in development is SBFM-PL4, an anti-coronavirus treatment compound. In addition to its pharmaceutical endeavors, Sunshine Biopharma offers a range of nutritional supplements, including the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, and continues to develop and market other scientifically-formulated nutritional products. The company has forged a licensing agreement with the University of Georgia to further the development of its lead anti-coronavirus compound, SBFM-PL4. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.